VGXI Inc., Texas, US-based contract manufacturer of plasmid DNA, is gearing up for clinical trial quantity production of a potential DNA vaccine against the 2019-nCoV coronavirus that has spread globally from Wuhan, China, as part of a new agreement with Inovio Pharmaceuticals Inc.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?